CRBP stock forecast
Our latest prediction for Corbus Pharmaceuticals Holdings, Inc.'s stock price was made on the Nov. 12, 2019 when the stock price was at 4.36$.
In the short term (2weeks), CRBP's stock price should outperform the market by 3.94%. During that period the price should oscillate between -8.11% and +12.53%.
In the medium term (3months), CRBP's stock price should outperform the market by 1.56%. During that period the price should oscillate between -20.31% and +31.03%.Get email alerts
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
At the moment the company generates 35M USD in revenues.
On its last earning announcement, the company reported a loss of -1.02$ per share.
The book value per share is 0.97$
Three months stock forecastNov. 12, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|